SCHEMBL21708007

SCHEMBL21708007

CCOC(=O)c1csc(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
MAPT P10636 3/20 0.53
LMNA P02545 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
GAA P10253 2/20 0.53
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
EGFR P00533 1/20 0.48
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10465369 0.89 L3MBTL1 (0.56) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL19667963 0.84 MAPT (0.62) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL9647639 0.80 CYP1A2 (0.54) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL18002737 0.80 MAPT (0.56) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL10464406 0.79 MAPT (0.65) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL4789312 0.79 SMN1; SMN2 (0.69) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL21708021 0.79 MAPT (0.68) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL15542308 0.78 CYP1A2 (0.52) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL2831045 0.78 L3MBTL1 (0.62) CYP1A2CYP2C19MAPTLMNANPSR1
SCHEMBL525606 0.78 MAOA (0.64) CYP1A2CYP2C19MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A CYP1A2 3477/4885CYP2C19 3845/4885MAPT 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.